Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Head and Neck Cancer

  Free Subscription


Articles published in J Nucl Med

Retrieve available abstracts of 34 articles:
HTML format



Single Articles


    June 2022
  1. ZHENG KH, Kroon J, Schoormans J, Gurney-Champion O, et al
    (89)Zr-labeled High-Density Lipoprotein Nanoparticle PET imaging reveals tumor uptake in patients with esophageal cancer.
    J Nucl Med. 2022 Jun 23. pii: jnumed.121.263330. doi: 10.2967/jnumed.121.263330.
    PubMed     Abstract available


  2. AVRAM AM, Giovanella L, Greenspan B, Lawson SA, et al
    SNMMI Procedure Standard/EANM Practice Guideline for Nuclear Medicine Evaluation and Therapy of Differentiated Thyroid Cancer: Abbreviated Version.
    J Nucl Med. 2022;63:15N-35N.
    PubMed    


    May 2022
  3. SUBRAMANIAM RM, Duan F, Romanoff J, Yu JQ, et al
    (18)F FDG PET/CT Staging of Head and Neck Cancer: Inter-observer agreement and accuracy - Results from multicenter ACRIN 6685 Clinical Trial.
    J Nucl Med. 2022 May 12. pii: jnumed.122.263902. doi: 10.2967/jnumed.122.263902.
    PubMed     Abstract available


  4. VERHOEFF SR, van de Donk PP, Aarntzen EHJG, Oosting SF, et al
    (89)Zr-DFO-durvalumab PET/CT prior to durvalumab treatment in patients with recurrent or metastatic head and neck cancer.
    J Nucl Med. 2022 May 5. pii: jnumed.121.263470. doi: 10.2967/jnumed.121.263470.
    PubMed     Abstract available


    December 2021
  5. CREFF G, Jegoux F, Palard-Novello X, Depeursinge A, et al
    FDG-PET/CT-based prognostic survival model after surgery for head and neck cancer.
    J Nucl Med. 2021 Dec 9. pii: jnumed.121.262891. doi: 10.2967/jnumed.121.262891.
    PubMed     Abstract available


  6. RISOER LM, Clausen MM, Ujmajuridze Z, Farhadi M, et al
    Prognostic value of Urokinase-type Plasminogen Activator Receptor (uPAR)-PET/CT in Head and Neck Squamous Cell Carcinomas and Comparison with (18)F-FDG-PET/CT: A single-center prospective study.
    J Nucl Med. 2021 Dec 2. pii: jnumed.121.262866. doi: 10.2967/jnumed.121.262866.
    PubMed     Abstract available


  7. PROMTEANGTRONG C, Siripongsatian D, Jantarato A, Kunawudhi A, et al
    Head-to-head comparison of (68)Ga-FAPI-46 and (18)F-FDG PET/CT for evaluation of head and neck squamous cell carcinoma: a single-center exploratory study.
    J Nucl Med. 2021 Dec 2. pii: jnumed.121.262831. doi: 10.2967/jnumed.121.262831.
    PubMed     Abstract available


    September 2021
  8. GU B, Xu X, Zhang J, Ou X, et al
    The Added Value of (68)Ga-FAPI-04 PET/CT in Patients with Head and Neck Cancer of Unknown Primary with (18)F-FDG Negative Findings.
    J Nucl Med. 2021 Sep 30. pii: jnumed.121.262790. doi: 10.2967/jnumed.121.262790.
    PubMed     Abstract available


  9. VONK J, de Wit JG, Voskuil FJ, Tang YH, et al
    Epidermal growth factor receptor targeted fluorescence molecular imaging for postoperative lymph node assessment in patients with oral cancer.
    J Nucl Med. 2021 Sep 16. pii: jnumed.121.262530. doi: 10.2967/jnumed.121.262530.
    PubMed     Abstract available


    August 2021
  10. AVRAM AM, Zukotynski K, Nadel HR, Giovanella LM, et al
    MANAGEMENT OF DIFFERENTIATED THYROID CANCER: THE STANDARD OF CARE.
    J Nucl Med. 2021 Aug 19. pii: jnumed.121.262402. doi: 10.2967/jnumed.121.262402.
    PubMed     Abstract available


    July 2021
  11. GIOVANELLA L, Avram A, Clerc J
    Molecular Imaging for Thyrotoxicosis and Thyroid Nodules.
    J Nucl Med. 2021;62.
    PubMed     Abstract available


  12. BERNET VJ, Chindris AM
    Update on the Evaluation of Thyroid Nodules.
    J Nucl Med. 2021;62.
    PubMed     Abstract available


  13. DE SOUZA FRANCA PD, Guru N, Kostolansky AR, Mauguen A, et al
    PARP1: A Potential Molecular Marker to Identify Cancer During Colposcopy Procedures.
    J Nucl Med. 2021;62:941-948.
    PubMed     Abstract available


    March 2021
  14. HOPE TA, Graces C, Calais J, Ehman E, et al
    Accuracy of (18)F-fluorocholine PET for the detection of parathyroid adenomas: prospective single center study.
    J Nucl Med. 2021 Mar 5. pii: jnumed.120.256735. doi: 10.2967/jnumed.120.256735.
    PubMed     Abstract available


    February 2021
  15. BODET-MILIN C, Faivre-Chauvet A, Carlier T, Ansquer C, et al
    Anti-CEA pretargeted Immuno-PET shows higher sensitivity than DOPA-PET/CT to detect relapsing metastatic medullary thyroid carcinoma: Post- hoc analysis of the iPET-MTC study.
    J Nucl Med. 2021 Feb 5. pii: jnumed.120.252791. doi: 10.2967/jnumed.120.252791.
    PubMed     Abstract available


    January 2021
  16. WHITMAN J, Allen IE, Bergsland EK, Suh IA, et al
    Assessment and comparison of fluorocholine PET and sestamibi scans in identifying parathyroid adenomas: a meta-analysis.
    J Nucl Med. 2021 Jan 15. pii: jnumed.120.257303. doi: 10.2967/jnumed.120.257303.
    PubMed     Abstract available


    October 2020
  17. NISHIO N, van den Berg NS, Martin BA, van Keulen S, et al
    Photoacoustic Molecular Imaging for the Identification of Lymph Node Metastasis in Head and Neck Cancer using an anti-EGFR Antibody-Dye Conjugate.
    J Nucl Med. 2020 Oct 2. pii: jnumed.120.245241. doi: 10.2967/jnumed.120.245241.
    PubMed     Abstract available


    September 2020
  18. VALKEMA MJ, van der Wilk BJ, Eyck BM, Wijnhoven BPL, et al
    Surveillance of clinically complete responders using serial (18)F-FDG PET/CT scans in patients with esophageal cancer after neoadjuvant chemoradiotherapy.
    J Nucl Med. 2020 Sep 4. pii: jnumed.120.247981. doi: 10.2967/jnumed.120.247981.
    PubMed     Abstract available


    August 2020
  19. NICOLAY NH, Ruhle A, Wiedenmann N, Niedermann G, et al
    Lymphocyte Infiltration Determines the Hypoxia-Dependent Response to Definitive Chemoradiation in Head-and-Neck Cancer - Results from a Prospective Imaging Trial.
    J Nucl Med. 2020 Aug 28. pii: jnumed.120.248633. doi: 10.2967/jnumed.120.248633.
    PubMed     Abstract available


    May 2020
  20. CHENG L, Sa R, Luo Q, Fu H, et al
    Unexplained Hyperthyroglobulinemia in Differentiated Thyroid Cancer Patients Indicates Radioiodine Adjuvant Therapy: A Prospective Multicenter Study.
    J Nucl Med. 2020 May 1. pii: jnumed.120.243642. doi: 10.2967/jnumed.120.243642.
    PubMed     Abstract available


    April 2020
  21. PICCARDO A, Trimboli P, Bottoni G, Giovanella L, et al
    Radioiodine Ablation of Remaining Thyroid Lobe in Patients with Differentiated Thyroid Cancer Treated by Lobectomy. A systematic review and meta-analysis.
    J Nucl Med. 2020 Apr 24. pii: jnumed.120.244384. doi: 10.2967/jnumed.120.244384.
    PubMed     Abstract available


    March 2020
  22. DONOHOE KJ, Aloff J, Avram AM, Bennet KG, et al
    Appropriate Use Criteria for Nuclear Medicine in the Evaluation and Treatment of Differentiated Thyroid Cancer.
    J Nucl Med. 2020;61:375-396.
    PubMed    


  23. WU D, Gomes Lima CJ, Bloom G, Burman KD, et al
    Nationwide Survey on Implementation of 2011 Nuclear Regulatory Commission Policy on Release of Patients After (131)I Therapy for Thyroid Cancer.
    J Nucl Med. 2020;61:397-404.
    PubMed     Abstract available


  24. WU J, Gensheimer MF, Zhang N, Guo M, et al
    Tumor Subregion Evolution-Based Imaging Features to Assess Early Response and Predict Prognosis in Oropharyngeal Cancer.
    J Nucl Med. 2020;61:327-336.
    PubMed     Abstract available


    January 2020
  25. VERMANDEL M, Debruyne P, Beron A, Devos L, et al
    Management of patients with renal failure undergoing dialysis during (131)I therapy for thyroid cancer.
    J Nucl Med. 2020 Jan 10. pii: jnumed.119.232017. doi: 10.2967/jnumed.119.232017.
    PubMed     Abstract available


    August 2019
  26. LIU J, Liu R, Shen X, Zhu G, et al
    The Genetic Duet of BRAF V600E and TERT Promoter Mutations Robustly Predicts the Loss of Radioiodine Avidity in Recurrent Papillary Thyroid Cancer.
    J Nucl Med. 2019 Aug 2. pii: jnumed.119.227652. doi: 10.2967/jnumed.119.227652.
    PubMed     Abstract available


    June 2019
  27. VAN NOSTRAND D
    Sites Performing Dosimetry for Selection of Activity for (131)I Therapy for Differentiated Thyroid Cancer.
    J Nucl Med. 2019;60:20N-22N.
    PubMed    


  28. MEERSHOEK P, van den Berg NS, Brouwer OR, Teertstra HJ, et al
    Three-Dimensional Tumor Margin Demarcation Using the Hybrid Tracer Indocyanine Green-(99m)Tc-Nanocolloid: A Proof-of-Concept Study in Tongue Cancer Patients Scheduled for Sentinel Node Biopsy.
    J Nucl Med. 2019;60:764-769.
    PubMed     Abstract available


    March 2019
  29. ROLL W, Markwardt NA, Masthoff M, Helfen A, et al
    Multispectral optoacoustic tomography of benign and malignant thyroid disorders - a pilot study.
    J Nucl Med. 2019 Mar 8. pii: jnumed.118.222174. doi: 10.2967/jnumed.118.222174.
    PubMed     Abstract available


    February 2019
  30. WATABE T, Kaneda-Nakashima K, Liu Y, Shirakami Y, et al
    Enhancement of astatine-211 uptake via the sodium iodide symporter by the addition of ascorbic acid in targeted alpha therapy of thyroid cancer.
    J Nucl Med. 2019 Feb 22. pii: jnumed.118.222638. doi: 10.2967/jnumed.118.222638.
    PubMed     Abstract available


    November 2018
  31. ELMOKH O, Taelmann V, Radojewski P, Roelli MA, et al
    MEK inhibition induces therapeutic iodine uptake in a murine model of anaplastic thyroid cancer.
    J Nucl Med. 2018 Nov 21. pii: jnumed.118.216721. doi: 10.2967/jnumed.118.216721.
    PubMed     Abstract available


    October 2018
  32. DE ROSE F, Braeuer M, Braesch-Andersen S, Otto AM, et al
    Galectin-3 targeting in thyroid orthotopic tumors opens new ways to characterize thyroid cancer.
    J Nucl Med. 2018 Oct 25. pii: jnumed.118.219105. doi: 10.2967/jnumed.118.219105.
    PubMed     Abstract available


  33. BIKAS A, Wu D, Bethancourt E, Orquiza M, et al
    Detection at public facilities of (131)I in patients treated for differentiated thyroid cancer: the frequency, sites, management by security agents, and recommended physician documentation for patients.
    J Nucl Med. 2018 Oct 25. pii: jnumed.118.213256. doi: 10.2967/jnumed.118.213256.
    PubMed     Abstract available


  34. BACHER R, Hohberg M, Dietlein M, Wild M, et al
    Thyroid uptake and effective half-life of radioiodine in thyroid cancer patients at radioiodine therapy and follow-up whole-body scintigraphy either in hypothyroidism or under rhTSH.
    J Nucl Med. 2018 Oct 12. pii: jnumed.118.217638. doi: 10.2967/jnumed.118.217638.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: